Last reviewed · How we verify
Sham to ranibizumab
Ranibizumab is a monoclonal antibody that inhibits vascular endothelial growth factor A (VEGF-A), preventing angiogenesis.
Ranibizumab is a monoclonal antibody that inhibits vascular endothelial growth factor A (VEGF-A), preventing angiogenesis. Used for Treatment of neovascular (wet) age-related macular degeneration, Treatment of macular edema following retinal vein occlusion, Treatment of diabetic macular edema.
At a glance
| Generic name | Sham to ranibizumab |
|---|---|
| Sponsor | Novartis |
| Drug class | anti-VEGF agent |
| Target | VEGF-A |
| Modality | Small molecule |
| Therapeutic area | Ophthalmology |
| Phase | Phase 3 |
Mechanism of action
VEGF-A is a protein that promotes the formation of new blood vessels. By inhibiting VEGF-A, ranibizumab reduces the growth of new blood vessels in the eye, which can help slow vision loss in conditions like age-related macular degeneration.
Approved indications
- Treatment of neovascular (wet) age-related macular degeneration
- Treatment of macular edema following retinal vein occlusion
- Treatment of diabetic macular edema
Common side effects
- Intraocular inflammation
- Endophthalmitis
- Retinal detachment
Key clinical trials
- A Study to Evaluate the Efficacy and Safety of Faricimab in Patients With Choroidal Neovascularization Secondary to Pathologic Myopia (PHASE3)
- A Study to Investigate Vamikibart (RO7200220) in Diabetic Macular Edema (PHASE2)
- A Study to Investigate Vamikibart (RO7200220) in Combination With Ranibizumab in Diabetic Macular Edema (PHASE2)
- Stereotactic Radiotherapy for Wet AMD (STAR) (PHASE3)
- OPT-302 With Ranibizumab in Neovascular Age-related Macular Degeneration (nAMD) (PHASE3)
- A Study to Evaluate ASP8232 in Reducing Central Retinal Thickness in Subjects With Diabetic Macular Edema (DME) (PHASE2)
- A Phase 3 Safety and Efficacy Study of Fovista® (E10030) Intravitreous Administration in Combination With Lucentis® Compared to Lucentis® Monotherapy (PHASE3)
- A Phase 3 Safety and Efficacy Study of Fovista® (E10030) Intravitreous Administration in Combination With Lucentis® Compared to Lucentis® Monotherapy (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Sham to ranibizumab CI brief — competitive landscape report
- Sham to ranibizumab updates RSS · CI watch RSS
- Novartis portfolio CI